Curcumin Derivative CU4c Exhibits HDAC-Inhibitory and Anticancer Activities Against Human Lung Cancer Cells In Vitro and in Mouse Xenograft Models

Background/Objectives: Drug resistance and severe side effects caused by gemcitabine (Gem) and cisplatin (CDDP) are common. This study aimed to investigate the combined effects of CU4c and Gem or CDDP on lung cancer cells in vitro and in nude mouse xenograft models. Methods: Antiproliferative activity and drug interaction were evaluated using MTT and Chou–Talalay methods, respectively. Apoptosis induction and cell cycle arrest were analyzed by flow cytometry. The expression levels of proteins were evaluated by Western blot analysis. The HDAC-inhibitory activity of CU4c was confirmed in vitro, in silico, and in A549 cells. Results: CU4c inhibited the proliferation of A549 cells in a dose- and time-dependent manner but had little effect on the growth of noncancerous Vero cells. CU4c synergistically enhanced the antiproliferative activities of CDDP (at 24 h) and Gem (at 48 and 72 h) against A549 cells. Combined CU4c and CDDP notably inhibited A549 proliferation by triggering cell cycle arrest at S and G2/M phases at 24 h with elevated levels of p21 and p53 proteins. Combined CU4c and Gem induced cell cycle arrest at both the S and G2/M phases at 48 h via upregulating the expression of the p21 protein. CU4c enhanced the apoptotic effects of CDDP and Gem by increasing the Bax/Bcl-2 ratio, pERK1/2, and Ac-H3 levels. Combined CU4c and Gem significantly reduced tumor growth while minimizing visceral organ damage in animal study. Conclusions: These results suggest that CU4c enhances the anticancer activity of CDDP and Gem and reduces the toxicity of Gem in animal studies.

• Publication year

  2025

• Venue

  Pharmaceuticals

• Publication date

  2025-06-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/ph18070960PMID 40732250PMCID 12297909
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic Anti-Cancer Activities of Curcumin Derivative CU17 Combined with Gemcitabine Against A549 Non-Small-Cell Lung Cancer Cells

  2025influential reference
• Co-delivery of paclitaxel and curcumin loaded solid lipid nanoparticles for improved targeting of lung cancer: In vitro and in vivo investigation

  2024cited by this paper
• High-content analysis identified synergistic drug interactions between INK128, an mTOR inhibitor, and HDAC inhibitors in a non-small cell lung cancer cell line

  2024cited by this paper
• Curcumin Derivatives in Medicinal Chemistry: Potential Applications in Cancer Treatment

  2024cited by this paper
• Colchicine as a potential HDAC inhibitor: comparative binding energies and prospects for cancer therapy repurposing

  2024influential reference
• Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway

  2024cited by this paper
• Curcumin and PCI-34051 combined treatment ameliorates inflammation and fibrosis by affecting MAP kinase pathway

  2023cited by this paper
• Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment

  2023cited by this paper
• Tiliacora triandra Leaf Powder Ethanolic Extract in Combination with Cisplatin or Gemcitabine Synergistically Inhibits the Growth of Cholangiocarcinoma Cells In Vitro and in Nude Mouse Xenograft Models

  2023cited by this paper
• In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes

  2023cited by this paper
• HDAC Inhibitory and Anti-Cancer Activities of Curcumin and Curcumin Derivative CU17 against Human Lung Cancer A549 Cells

  2022influential reference
• Current trends in development of HDAC-based chemotherapeutics.

  2022cited by this paper
• Histological Effect of Gemcitabine on the Liver and Kidney of Male Rat with and without Melatonin

  2022cited by this paper
• Cell cycle regulation: p53-p21-RB signaling

  2022cited by this paper
• The role of BCL-2 family proteins in regulating apoptosis and cancer therapy

  2022cited by this paper
• Histone deacetylases modulate resistance to the therapy in lung cancer

  2022cited by this paper
• Anti‐Lung Cancer Activities of 1,2,3‐Triazole Curcumin Derivatives via Regulation of the MAPK/NF‐κB/STAT3 Signaling Pathways

  2021cited by this paper
• ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer

  2021cited by this paper
• The Role of Curcumin in Cancer Treatment

  2021cited by this paper
• Influence of side-chain changes on histone deacetylase inhibitory and cytotoxicity activities of curcuminoid derivatives.

  2020influential reference
• Antiproliferative effect and autophagy induction of curcumin derivative ZYX02‐Na on the human lung cancer cells A549

  2020influential reference
• Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications

  2019cited by this paper
• New histone deacetylase inhibitors and anticancer agents from Curcuma longa

  2019cited by this paper
• Epigenetic Regulation of p21cip1/waf1 in Human Cancer

  2019cited by this paper
• Megakaryocytes in Bone Metastasis: Protection or Progression?

  2019cited by this paper
• Gemcitabine induced cytotoxicity, DNA damage and hepatic injury in laboratory mice

  2018cited by this paper
• Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells

  2018cited by this paper
• Curcumin: A Natural Pan-HDAC Inhibitor in Cancer.

  2018cited by this paper
• Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung

  2018cited by this paper
• Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?

  2018cited by this paper
• Salvianolic acid B reverses multidrug resistance in nude mice bearing human colon cancer stem cells

  2018cited by this paper
• Identification of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer

  2018cited by this paper
• A mono-carbonyl analog of curcumin induces apoptosis in drug-resistant EGFR-mutant lung cancer through the generation of oxidative stress and mitochondrial dysfunction

  2018cited by this paper
• Functions and mechanisms of non-histone protein acetylation

  2018cited by this paper
• Chemotherapy for Lung Cancer in the Era of Personalized Medicine

  2018cited by this paper
• Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions

  2017cited by this paper
• Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer.

  2017cited by this paper
• MicroRNA: A novel target of curcumin in cancer therapy

  2017cited by this paper
• In vitro anticancer and cytotoxic activities of some plant extracts on HeLa and Vero cell lines.

  2017cited by this paper
• HDACs and HDAC Inhibitors in Cancer Development and Therapy.

  2016cited by this paper
• Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells

  2016cited by this paper
• p21(WAF1) Mediates Cell-Cycle Inhibition, Relevant to Cancer Suppression and Therapy.

  2016cited by this paper
• Effects of histone deacetylase inhibitor trichostatin A combined with cisplatin on apoptosis of A549 cell line

  2015cited by this paper
• Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread.

  2015cited by this paper
• Curcumin alters gene expression-associated DNA damage, cell cycle, cell survival and cell migration and invasion in NCI-H460 human lung cancer cells in vitro.

  2015cited by this paper
• The role of p21waf1/cip1 and p27Kip1 in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma

  2014cited by this paper
• Histone Deacetylases

  2014cited by this paper
• Targeting cell cycle regulation in cancer therapy.

  2013cited by this paper
• Treatment of lung cancer using nanoparticle drug delivery systems.

  2013cited by this paper
• Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells

  2013cited by this paper
• Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine.

  2011cited by this paper
• Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors.

  2010cited by this paper
• ERK and cell death: Mechanisms of ERK‐induced cell death – apoptosis, autophagy and senescence

  2010cited by this paper
• Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.

  2010cited by this paper
• Cisplatin-Induced DNA Damage Activates Replication Checkpoint Signaling Components that Differentially Affect Tumor Cell Survival

  2009cited by this paper
• Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.

  2009cited by this paper
• Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating akt and p38 mAPK

  2007cited by this paper
• Synthesis and biological evaluation of polyhydroxycurcuminoids.

  2005cited by this paper
• Cell-cycle dysregulation and anticancer therapy.

  2003cited by this paper
• Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model.

  2001cited by this paper
• Requirement for ERK Activation in Cisplatin-induced Apoptosis*

  2000cited by this paper
• Binucleation and polyploidization patterns in developmental and regenerative rat liver growth

  1993cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• No citing papers are available for this paper.